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Humans can be exposed to a pano-
ply of agents and actions including 
chemicals, nanomaterials, metals, 
and complex mixtures. The link 
between these exposures and pos-
sible clinical sequelae including cancer 
is often poorly understood. Historically, regula-
tors have addressed such uncertainty by applying linear low-
dose defaults when establishing cancer risk estimates for suspected or 
known carcinogens. However, in recent years, cancer risk assessments 
have become increasingly sophisticated. An important component of 
this increased sophistication is the relatively new ability to consider 
the mode of action by which a substance might exert procarcinogenic, 
anticarcinogenic, or neutral effects. Knowledge regarding the mode of 
action can elucidate the relevance to human health associated with the 
particular exposure. In addition, technological advances in molecular 
biology and computational analyses increasingly contribute to screening 
for the potential for substances to cause cancer, or to inform particular 
areas of risk assessments. Cancer Risk Assessment provides an excellent 
synthesis of the aforementioned topics, as well as others essential for 
students becoming acquainted with the field or practitioners struggling 
to stay abreast of the rapid pace of emerging concepts in the literature.
This carefully edited book represents a multiauthor compilation 
of chapters contributed by well-known experts in the field. The author 
roster is well-balanced across all sectors of the scientific community, 
with primary contributions from academia, consulting companies, 
and government agencies. The book is divided into six major parts 
presented in a logical format and amenable to the classroom setting or 
individual study. 
A historical and current overview of cancer risk assessment is pro-
vided in Part I. The science and regulatory processes that lead to policy 
decisions are discussed, along with shaping chemical-control frame-
works such as the European Commission’s Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) regulation. 
Part II begins with a historical account of cancer, followed by 
advances in the cell biology of cancers. The classic and mechanistically 
groundbreaking studies on polycyclic aromatic hydrocarbons (PAHs) 
are used to convey critical concepts on multistage carcinogenesis, 
including initiation, promotion, and progression. From there, specific 
types of dose–response relationship, such as the sometimes controver-
sial hormesis mechanism and always controversial biological thresholds 
for genotoxic carcinogens, are discussed, thereby supplementing the 
understanding of these latter critical concepts. 
Part III focuses on specific types of genotoxicity testing. Although 
methodological and analytical aspects of this topic have been addressed 
extensively in available books, Cancer Risk Assessment provides the finest 
presentation I have seen on regulatory aspects of genotoxicity, specific 
genotoxicity assays, and interpretative guidance for the various assays. 
The wealth of information conveyed on this important topic alone jus-
tifies purchasing this book. 
In Part IV, the reader is introduced to a specific framework for 
analyzing mode of action and human relevance of chemical-induced 
tumors. Specific examples are discussed, including PPAR-α and liver 
tumors, α2u-globulin nephropathy, chronic progressive nephropathy, 
and urinary tract calculi and bladder tumors. One notable limitation in 
this part was the absence of a chapter devoted to thyroid follicular cell 
tumors. Because the mode of action for these types of tumors has been 
incorporated into regulatory guidance, Part IV is incomplete without 
presentation on this topic.
Emerging technologies in cancer risk assessment are elucidated in 
Part V. The section opens with one of the most concise yet comprehen-
sive discussions available on quantitative structure–activity relationship 
(QSAR) evaluations. This chapter is a tour de force for readers engaged 
in the research and development of new molecules. From QSARs, the 
reader is transitioned to physiologically based pharmacokinetic (PBPK) 
models. The application of these models is discussed and includes inter- 
and intraspecies extrapolations, route-to-route exposure extrapolations, 
and highly challenging extrapolations from individual carcinogens to 
mixtures. Specific case studies are also presented. Thereafter, genomic 
applications to risk assessment are discussed, along with case studies. 
Part V concludes with a brief recap on PBPK modeling and discusses 
future research initiatives in computational toxicology.
Part VI describes general approaches for quantifying cancer risks. 
Quantification based on both linear low-dose- and nonlinear low-dose-
extrapolations is presented. These discussions are well balanced and are 
recommended reading. Of particular interest in this part is a timely pre-
sentation and update on the appropriateness of combining neoplasms 
for the evaluation of rodent carcinogenesis studies. This information 
will undoubtedly be of significant value to regulatory risk assessors, who 
have relied up until now on a 1986 publication by a common author of 
this chapter. Finally, this part concludes with a step-by-step instruc-
tional discussion on exposure reconstruction and cancer risk estimation. 
In summary, Cancer Risk Assessment is a well-written book that 
reads more like the story of risk assessment than a traditional textbook 
as one topic flows seamlessly to the next logical point. This book pro-
vides extensive coverage in the field, with the topics covered in some 
cases being so timely that they are not yet available in other texts. 
However, even topics that have received extensive coverage in other 
sources are presented in a manner that warrants review. Novice readers 
and experts alike will benefit from having this comprehensive text as a 
learning aid or a reliable reference with a well-worn cover.
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